UPDATE: Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
22 Julio 2009 - 10:08AM
PR Newswire (US)
/C O R R E C T I O N -- Access Pharmaceuticals, Inc./ DALLAS, July
22 /PRNewswire-FirstCall/ -- In the news release, Access
Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock
Conference, issued earlier today by Access Pharmaceuticals, Inc.
over PR Newswire, we are advised by the company that in the
headline and throughout the release "Jessup" should read as
"Jesup". The complete, corrected release follows: Access
Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock
Conference Access to Provide Details on MuGard Launch in Europe
ACCESS PHARMACEUTICALS, INC. (OTC:ACCP) (BULLETIN BOARD: ACCP)
announced today that Jeffrey B. Davis, President & CEO, will
present at the Jesup & Lamont 2009 Growth Stock Conference
organized by the LifeTech Capital Group on Thursday, July 30, 2009
at 10:45 am EDT. The presentation will occur live and will be held
at the Waldorf Astoria Boca Beach Club in Boca Raton, Florida. "We
are pleased to have the opportunity to present Access
Pharmaceuticals to the large group of institutional and retail
investors that attend Jesup's annual growth stock conference,"
stated Jeffrey B. Davis, Access' President & CEO. "The
conference provides a forum for Access to highlight in many product
programs, and specifically the very significant and positive
initial results and feedback from the commercial launch of MuGard,
our FDA approved treatment for oral mucositis. Initial clinical
feedback and experience exceeds our expectations." About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical
company that develops and commercializes propriety products for the
treatment and supportive care of cancer patients. Access' products
include ProLindac(TM), currently in Phase 2 clinical testing of
patients with ovarian cancer, and MuGard(TM) for the management of
patients with mucositis. The company also has other advanced drug
delivery technologies including Cobalamin(TM)-mediated targeted
delivery and oral drug delivery, its proprietary nanopolymer
delivery technology based on the natural vitamin B12 uptake
mechanism; Angiolix , a humanized monoclonal antibody which acts as
an anti-angiogenesis factor and is targeted to breast cancer; and
Thiarabine, a new generation nucleoside analog which has
demonstrated both pre-clinical and clinical activity in certain
cancers. For additional information on Access Pharmaceuticals,
please visit our website at http://www.accesspharma.com/. This
press release contains certain statements that are forward-looking
within the meaning of Section 27a of the Securities Act of 1933, as
amended, and that involve risks and uncertainties. These statements
include those relating to: clinical trial plans and timelines and
clinical results for ProLindac and product candidates acquired in
the MacroChem transaction, our ability to execute licensing
agreements in the future, Access' plans to continue and initiate
clinical trials, the value of its products in the market (including
MuGard and the size of the overall market for mucositis products),
its ability to achieve clinical and commercial success and its
ability to successfully develop marketed products. These statements
are subject to numerous risks, including but not limited Access'
need to obtain additional financing in order to continue the
clinical trial and operations and to the risks detailed in Access'
Annual Reports on Form 10-K and other reports filed by Access with
the Securities and Exchange Commission. DATASOURCE: Access
Pharmaceuticals, Inc. CONTACT: Company, Stephen B. Thompson, Vice
President, Chief Financial Officer of Access Pharmaceuticals, Inc.,
+1-214-905-5100; Investor Relations, Donald C. Weinberger or Diana
Bittner (media), both of Wolfe Axelrod Weinberger Assoc. LLC,
+1-212-370-4500, for Access Pharmaceuticals, Inc. Web Site:
http://accesspharma.com/index.shtml
Copyright